Category: News

January 21, 2022

In October, the Geneva-based Medicines Patent Pool, a United Nations-backed public health group announced a voluntary licensing agreement by which Merck would license the drug to companies that meet certain quality-assurance specifications. Neither Merck nor its development partners will receive […]

January 19, 2022

64x Bio, a fledgling synthetic cell and gene therapy manufacturer, brought in $55 million in a series A round of fundraising. The company, which has about 10 employees and was founded in 2020 out of the Harvard Department of Genetics, […]

January 10, 2022

The German group is paying $40 million upfront to kick off the alliance, which is focusing on the development of up to five CRISPR drugs that can be delivered in vivo for liver-targeted diseases. There is another $1 billion in […]

January 7, 2022

AstraZeneca is stepping up its pursuit of a rare disease market targeted by Alnylam and Pfizer. Having entered the ATTR space through its takeover of Alexion, AstraZeneca is paying $30 million for worldwide rights to Neurimmune’s NI006 in its second […]

January 6, 2022

Novartis is getting back into bed with Alnylam. More than a decade after severing its ties to the RNAi pioneer, Novartis has returned to the deal table for an ambitious early-stage collaboration to restore liver function in patients with end-stage […]

December 30, 2021

The latest to reach the regulatory stage is teclistamab, one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J’s Janssen division stemming from its longstanding and fertile collaboration with Danish biotech Genmab. That alliance also generated Darzalex […]

December 27, 2021

Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been granted a fast-track tag by the FDA, setting up a potentially swift path through the regulatory process. The drug is the next in line behind the pair’s approved therapy Aduhelm, which […]

December 22, 2021

We thought we’d finally get to see what a post-pandemic world looked like in 2022, but thanks to omicron, it seems we’re in for another round. Biotech has been shaped by the pandemic in ways that may be permanent, just […]

December 21, 2021

President Joe Biden laid out a comprehensive plan on Tuesday to help Americans navigate a tough winter facing the Omicron variant, but he also made an impassioned plea for all eligible American to get vaccines and boosters. “For the folks […]

December 14, 2021

Without “decisive action” cancer deaths across the European Union (EU) will increase by almost a quarter by 2035, making it the bloc’s leading cause of death. Expediating access to new treatments is key to avoiding this devastating outcome, according to […]

December 13, 2021

Westminster has promised additional support for the devolved administrations in Scotland, Wales and Northern Ireland to step up the booster campaign, and Scotland has already said it intends to match England’s target. The move comes as Prime Minister Boris Johnson […]

December 9, 2021

Unlike some of its Big Pharma peers, Novartis has not been at the forefront of creating new vaccines and treatments against COVID: Now, however, it’s taking its massive R&D budget and targeting not just the current pandemic, but all coronaviruses. […]